Dahong Zhang

Dahong Zhang


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2022 in Journal of Controlled Release
Verified
Journal Article
Open access
BZBin Zheng
Bin Zheng
ZLZhenghong Liu
Zhenghong Liu
HWHeng Wang
Heng Wang
LSLi Sun
Li Sun
WLWing-Fu Lai
Wing-Fu Lai
DZDahong Zhang
Dahong Zhang
Intravesical chemotherapy is generally used in the clinic for treating bladder cancer (BCa), but its efficacy is limited due to the permeation barrier and side effects caused by the off-targeting of normal urothelial cells. In this study, BCa cell-derived membrane nanovesicles were used as drug carriers, and their homologous tumor-targeting capacity was utilized. A BCa-targeting hendeca-arginine peptide was functionalized onto the nanovesicles to impart a mucus-penetrating ability and thus overcome the permeation barrier. The tumor-targeting and mucus-penetrating nanovesicles were stable in urine, were highly permeable to the glycosaminoglycan layer, and specifically targeted BCa. The vesicles were internalized through caveolin-mediated endocytosis, were transported to nonlysosome-localized intracellular regions, and efficiently infiltrated bladder tumor spheroids. In in vivo intravesical chemotherapy, the nanovesicles achieved chemo-resection in murine orthotopic BCa models. This BCa-targeting and mucus-penetrating drug delivery system may be promising for the intravesical chemotherapy of BCa.

25 October 2024 in Drug Delivery
Verified
Journal Article
Open access
HLHaichang Li
Haichang Li
ZLZhenghong Liu
Zhenghong Liu
DZDahong Zhang
Dahong Zhang
DZDahong Zhang
Dahong Zhang
Hydrogels, comprising 3D hydrophilic polymer networks, have emerged as promising biomaterial candidates for emulating the structure of biological tissues and delivering drugs through topical administration with good biocompatibility. Nanozymes can catalyze endogenous biomolecules, thereby initiating or inhibiting in vivo biological processes. A nanozyme-hydrogel composite inherits the biological functions of hydrogels and nanozymes, where the nanozyme serves as the catalytic core and the hydrogel forms the structural scaffold. Moreover, the composite can concentrate nanozymes in targeted lesions and catalyze the binding of a specific group of substrates, resulting in pathological microenvironment remodeling and drug-penetrating barrier impairment. The composite also shields nanozymes to prevent burst release during catalytic production and reduce related toxicity. Currently, the application of these composites has been extended to antibacterial, anti-inflammatory, anticancer, and tissue repair applications. In this review, we elucidate the preparation methods for nanozyme-hydrogel composites, provide compelling evidence of their advantages in drug delivery and provide a comprehensive overview of their biological application.

20 June 2012 in International Urogynecology Journal
Verified
Journal Article
Closed access
PDF file
QZQi Zhang
Qi Zhang
ZYZaiyuan Ye
Zaiyuan Ye
FLFeng Liu
Feng Liu
XQXiaolong Qi
Xiaolong Qi
CSChangming Shao
Changming Shao
DZDahong Zhang
Dahong Zhang

1 January 2014 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
QZQi Zhang
Qi Zhang
HWHuiju Wang
Huiju Wang
LRLigang Ren
Ligang Ren
XQXiaolong Qi
Xiaolong Qi
FLFeng Liu
Feng Liu
DZDahong Zhang
Dahong Zhang
Primary synovial sarcoma of the prostate is an uncommon malignant tumor. There are few cases reported in the English medical literature to date. Here, we present a case of 22-year-old man with primary synovial sarcoma of the prostate metastatic to the liver and lung. To our knowledge, only six reports of synovial sarcoma involving the prostate have been previously published. We also reviewed the previous treatments and prognoses in previous case reports and evaluate the proper treatment for this disease.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
QZQi Zhang
Qi Zhang
JWJunxiu Wu
Junxiu Wu
XCXinpeng Chen
Xinpeng Chen
MZMing Zhao
Ming Zhao
DZDahong Zhang
Dahong Zhang
FGFeng Gao
Feng Gao
Objective. This work analyzes the role of versican (VCAN) on bladder cancer (BLCA). Versican (VCAN) is a chondroitin sulfate proteoglycan which is important for tumorigenesis and the development of cancer. However, the expression of VCAN on human bladder cancer (BLCA) has been rarely reported. Methods. The clinical significance of VCAN in BLCA has been determined by our bioinformatics tools. Then, we performed immunohistochemical staining (IHC) and analyzed the correlation between VCAN expression and clinicopathological features. Results. The bioinformatics results reveal that a high VCAN mRNA level was significantly associated with stage, histological subtype, molecular subtype, and metastasis in BLCA. Furthermore, IHC reveals that expression of VCAN was significantly correlated with the number of tumors, invasion depth, lymph node metastasis, distant metastasis, and histological grade. Kaplan‐Meier survival analysis reveals that patients with a high expression of VCAN have poor prognosis than those patients with a low expression of VCAN. According to our result from the bioinformatics database, the mechanism of VCAN in BLCA revealed that VCAN was related to FBN1 and genes of the ECM remodeling pathway (MMP1, MMP2). Conclusion. VCAN expression might be included in the process of carcinogenesis and prognosis. Hence, VCAN could be a reliable biomarker of the clinical prognosis on BLCA.

1 August 2014 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
QZQi Zhang
Qi Zhang
ZZZhongsheng Zhao
Zhongsheng Zhao
YMYingyu Ma
Yingyu Ma
HWHuiju Wang
Huiju Wang
JMJie Ma
Jie Ma
DZDahong Zhang
Dahong Zhang